The domestic 4 trillion biomedical market has entered the "awakening era"

【Pharmaceutical Network Market Analysis】 In recent years, with the continuous introduction of favorable policies for biomedicine, the biomedical industry has achieved rapid development
.
According to statistics, in 2021, the drug review center accepted a total of 1062 applications for the registration of Class 1 innovative drugs (597 varieties), an increase of about 57%
year-on-year.
As of 2021, the market size of China's biomedical industry is 3.
97 trillion yuan, and it is estimated that by 2023, the market size of China's biomedical industry is expected to exceed 4 trillion yuan
.
It is reported that the recent biomedical sector policy is once again centrally released, such as September 7, the National Standing Committee clearly mentioned the support for hospitals in the "equipment purchase and renovation of new loans, the
implementation of phased encouragement policies".
On September 13, the National Standing Committee decided to support the renovation of equipment in some fields with special refinancing and financial discounts to achieve the goal
of expanding market demand and increasing development potential.
Industry insiders said that the recent biomedical sector policy is conducive to the centralized release, and the industry prosperity has ushered in a marginal improvement
.
It is understood that in the first half of this year, many domestic biomedical enterprises have achieved good results
.
For example, WuXi AppTec benefited from the rapid growth of revenue, and the net profit attributable to the mother and the net profit after deduction of non-parent in the first half of this year increased by 73.
29% and 81% respectively year-on-year to 4.
636 billion yuan and 3.
85 billion yuan
.
In addition, CSPC Pharmaceutical Group, WuXi Biologics, Xinhecheng, Changchun High-tech and other net profit attributable to the mother in the first half of this year and net profit after deduction of non-deduction reached 2 billion yuan
.
Analysts pointed out that the biomedical industry is rapidly developing from a high-tech industry with development potential to a high-tech pillar industry
.
The future will enter a period of
rapid development.
With the advancement of biotechnology, the continuous growth of the total population and the intensification of the aging of society, the size of the biomedical market will develop steadily, and China is occupying an increasingly important position
in the field of biomedicine.
Especially in the field of emerging technologies, China is more likely to synchronize with the world and even overtake in curves
.
It is reported that at present, the key development of biological products in China includes genetic engineering drugs, the development of active proteins and polypeptide drugs, the extraction of Chinese herbal medicines and their effective bioactive ingredients, fermentation production, the development of various vaccines, monoclonal antibodies and enzyme diagnostic and therapeutic reagents, and the development of targeted drugs
.
The strong market demand for these types of drugs will also drive the rapid development
of the industry.
In recent years, China has continued to deepen the regional layout of the biomedical industry, which has achieved the beginning of the upsurge of pharmaceutical companies
.
For example, in terms of regional layout, the "14th Five-Year Plan" for the development of the bioeconomy proposes that in the Beijing-Tianjin-Hebei, Yangtze River Delta, Guangdong-Hong Kong-Macao Greater Bay Area, Chengdu-Chongqing Area Twin Cities Economic Circle and other regions, the city as the carrier layout to build a bioeconomic pilot zone, around the biomedicine, biological agriculture, bioenergy, bioenvironmental protection and other fields to carry out scientific and technological innovation and reform pilots, to promote the development of China's bio-economic growth
。 A number of biomedical industry clusters have accelerated their formation, among which Beijing has formed three major pharmaceutical and life science industry clusters: Changping Zhongguancun Life Science Park, Yizhuang Economic and Technological Development Zone and Daxing Biomedical Industry Base; Jiangsu Province proposes to strive to build a 100-billion-level biomedical industry innovation cluster in Nanjing, Suzhou, Taizhou, Lianyungang and other
regions.
The industry said that in order to accelerate the improvement of biomedical innovation capabilities, in the future, China also needs to target key areas to implement major national science and technology projects and key research and development plans, deploy major national scientific and technological infrastructure in advance, build a national strategic scientific and technological force in the biological field, and fight a key core technology battle
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.